Abstract
Bryostatin 1 is a naturally occurring macrocyclic lactone with promising antitumour and immunomodulatory function in preclinical and phase I clinical investigations. In this phase II study, 17 patients with progressive non-Hodgkin’s lymphoma of indolent type (NHL), previously treated with chemotherapy, received a median of 6 (range 1–9) intravenous infusions of 25 μg/m2 bryostatin 1 given once weekly over 24 hours. In 14 evaluable patients no responses were seen. Stable disease was attained in one patient for 9 months. The principal toxicities were myalgia and phlebitis. Treatment was discontinued early because of toxicity alone (phlebitis) in 2 patients, toxicity in addition to progressive disease in 3 patients (myalgia and phlebitis n = 2; thrombocytopenia n = 1) and progressive disease in 5 patients. The results fail to demonstrate efficacy of this regimen of bryostatin 1 in the treatment of NHL. In light of preclinical data that demonstrate synergy between bryostatin 1 and several cytotoxic agents and cytokines, clinical studies to investigate bryostatin 1 in combination are warranted. We also present data to demonstrate that central venous lines may be used in future studies to avoid phlebitis. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Al-Katib AM, Smith MR, Kamanda WS, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B and Mohammed RM (1998) Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 4: 1305–1314
Basu A and Lazo JS (1992) Sensitisation of human cervical carcinoma cells to cis-diamminediachloroplatinum(II) by bryostatin 1. Cancer Res 52(11): 3119–3124
Berkow RL, Schlabach L, Dodson R, Benjamin WJ, Pettit GR, Rustagi P and Kraft AS (1993) In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res 53: 2810–2815
Buchner K (2000) The role of protein kinase C in the regulation of cell growth and in signalling to the cell nucleus. J Cancer Res Clin Oncol 126(1): 1–11
Cheung AP, Hallock YF, Vishnuvajjala BR, Nguyenle T and Wang E (1998). Invest New Drugs 16: 227–236
Elgie AW, Sargent JM, Alton P, Peters GJ, Noordhuis P, Williamson CJ and Taylor CG (1998) Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML. Leuk Res 22(4): 373–378
Gehan A (1961) The determination of the number of patients required in a preliminary and a follow up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346–353
Gonzalez R, Ebbinghaus S, Henthorn TK, Miller D and Kraft AS (1999) Treatment of patients with metastatic melanoma with bryostatin 1 – a phase II study. Melanoma Res 9(6): 599–606
Hickman PF, Kemp GJ, Thompson CH, Salisbury AJ, Wade K, Harris AL and Radda GK (1995) Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study. Br J Cancer 72(4): 998–1003
Hornung RL, Pearson JW, Beckwith M and Longo DL (1992) Preclinical evaluation of bryostatin as an anticancer agent against several murine tumour cell lines: in vitro versus in vivo activity. Cancer Res 52: 101–107
Jayson GC, Crowther D, Prendiville J, McGown A, Scheid C, Stern P, Young R, Brenchley P, Chang J and Owens S and Pettit GR (1995) A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. B J Cancer 72: 461–468
Kaubisch A, Kelsen DP, Saltz L, Kemeny N, O’Reilly E, Ilson D, Endres S, Barazzuol J and Schwartz GK (1999). A phase I trial of weekly sequential bryostatin-1 and paclitaxel in patients with advanced solid tumours,
Khan P, McGown AT, Dawson MJ, Jayson G, Prendiville JA, Pettit GR and Crowther D (1998) High Performance liquid chromatographic assay for the novel antitumour drug, bryostatin-1, incorporating a serum extraction technique. J Chromatogr B Biomed Sci Appl 709(1): 113–117
Koutcher JA, Motwani M, Zakian KL, Li XK, Matei C, Dyke JP, Ballon D, Yoo HH and Schwartz GK (2000) The in vivo effect of bryostatin 1 on paclitaxel-induced tumour growth mitotic entry, and blood flow. Clin Cancer Res 6(4): 1498–1507
Maki A, Diwakaran H, Redman B, Al-Asfar S, Pettit GR, Mohammed RM and Al-Katib A (1995) The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anticancer Drugs 6: 392–397
May WS, Sharkis SJ, Esa AH, Gebbia U, Kraft AS, Pettit GR and Sensenbrenner L (1987) Antineoplastic bryostatins are multipotential stimulators of human haematopoietic progenitor cells. Proc Natl Acad Sci 84: 8483–8487
McGown AT, Jayson G, Pettit GR, Haran MS, Ward TH and Crowther D (1998) Bryostatin 1 – tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro. Br J Cancer 77(2): 216–220
Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1): 207–214
Mohammed RM, Al-Katib A, Pettit RG and Sensenbrenner LL (1993) Differential effects of bryostatin 1 on human non-Hodgkin’s lymphoma cell lines. Leukaemia Research 17: 1–8
Mohammed RM, Al-Katib Pettit GR and Sensenbrenner LL (1994) Successful treatment of human Waldenstrom’s macroglobulinaemia with combination biological and chemotherapy agents. Cancer Res 54: 165
Mohammed RM, Diwakaran H, Maki A, Emara MA, Pettit GR, Redman B and Al-katib A (1995) Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk Res 19: 667–673
Mohammed RM, Beck FW, Katato K, Hardy N, Wall N and Al-Katib A (1998) Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukaemia cell line (WSU-CLL): association with increased ratios of dCK/5-NT and Bax/Bcl-2. Biol Chem 379(10): 1253–1261
Nishizuka Y (1986) Studies and perspectives of protein kinase C. Science 233: 305–312
Pettit GR, Herald CL and Doubek DL (1982) Isolation and structure of bryostatin 1. J Am Chem soc 104: 6846–6848
Philip AP, Rea D, Thavasu P, Carmichael J, Stuart NSA, Rockett H, Talbot DC, Ganeson T, Pettit GR, Balkwill F and Harris AL (1993) Phase I study of bryostatin 1: Assessment of interleukin 6 and tumor necrosis factor α induction in vivo. J Natl Cancer Institute 85(22): 1812–1818
Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M and Pettit GR (1993) A Phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 68: 418–424
Propper DJ, Macaulay V, O’Byrne KJ, Braybrooke JP, Wilner SM, Ganesean TS, Talbot DC and Harris AL (1998) A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 78(10): 1337–1341
Rosenthal MA, Oratz R, Liebes L, Cahr MH and Muggia FM (1999). Phase I study of bryostatin-1 (NSC 339555) and Cisplatin in Advanced Malignancies,
Scheid C, Prendiville J, Jayson G, Crowther D, Fox B, Pettit GR and Stern PL (1994) Immunomodulation in patients receiving intravenous bryostatin 1 in a phase 1 clinical study: comparison with effects of bryostatin 1 on lymphocyte function in vitro. Cancer Immunol Immunother 39: 223–230
Sharkis SJ, Jones RJ, Bellis ML, Demitri GD, Griffin JD, Civin C and May WS (1990) The action of bryostatin on normal human haematopoietic progenitors is mediated by accessory cell release of growth factors. Blood 76: 716–720
Stansfeld AG, Diebold G, Noel H, Kapanci Y, Rilke F, Kelenyi G, Sundstrom C, Lennert K, van-Unnik JA and Mioduszewska O (1988) Updated Kiel Classification for lymphomas (letter). Lancet 1: 292–293
Thompson CH, Macaulay VM, O’Byrne KJ, Kemp GJ, Wilner SM, Talbot DC, Harris AL and Radda GK (1996) Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply. Br J Cancer 73(10): 1161–1165
Varterasian ML, Mohammed RM, Eilender DS, Hulbard K, Rodriguez DH, Pemberton PA, Pluda JM, Dan MD, Pettit GR, Chen BDM and Al-Katib AM (1998) Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. J Clin Oncol 16(1): 56–62
Varterasian ML, Mohammed RM, Shurafa MS, Hulbard K, Pemberton PA, Rodriguez DH, Spadoni V, Eilender DS, Murgo A, Wall N, Dan M and Al-Katib AM (2000) Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Clin Cancer Res 6: 825–828
Weitman S, Langevin AM, Berkow RL, Thomas PJ, Hurwitz CA, Kraft AS, Dubowy RL, Smith DL and Bernstein M (1999) A Phase I trial of bryostatin 1 in children with refractory solid tumours: a Pediatric Oncology Group study. Clin Cancer Res 5(9): 2344–2348
Wojtowicz-Praga SM, Dickson RB and Hawkins MJ (1997) Matrix metalloproteinase inhibitors. Investigational New Drugs 15: 61–75
Author information
Authors and Affiliations
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Blackhall, F., Ranson, M., Radford, J. et al. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Br J Cancer 84, 465–469 (2001). https://doi.org/10.1054/bjoc.2000.1624
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1624
Keywords
This article is cited by
-
Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma
Modern Pathology (2005)
-
Protein kinase C inhibitors
Current Oncology Reports (2002)